BMS Temporarily Transfers Allergy Drug Pemilaston To Alfresa Pharma
This article was originally published in PharmAsia News
Executive Summary
U.S. drugmaker Bristol-Myers Squibb announced Nov. 26 that the company has transferred manufacturing and marketing rights of allergy drug Pemilaston (pemirolast) in Japan to Alfresa Pharma until the end of March 2009. A subsidiary of Alfresa Holdings, Alfresa Pharma has been focusing on allergy drugs and pemirolast will strengthen its product lineup, while Bristol is consolidating resources on its cancer and HIV drug business. (Click here for more - Japanese language
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.